Clodronate prevents prosthetic migration: a randomized radiostereometric study of 50 total knee patients.
In a double-blind study, we randomized 50 patients to receive peroral clodronate medication or placebo from 3 weeks before until 6 months after a total knee replacement with a cemented NexGen implant. Migration of the tibial components was measured by radiostereometry at 1 year. Clodronate reduced prosthetic migration, as measured by maximum total point motion, from 0.40 mm to 0.29 mm (p = 0.01). This confirms that the early postoperative migration is related to bone resorption and thus the biology of the bone bed. Since early migration is related to late loosening, 6 months of clodronate medication might reduce the risk of loosening.
Hilding
M
M
Department of Orthopedics and Center for Clinical Research, Uppsala University, Central Hospital of Västerås, Sweden. maria.hilding@ltvastmanland.se
Ryd
L
L
Toksvig-Larsen
S
S
Aspenberg
P
P
D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D001862:Bone Resorption; D004002:Clodronic Acid / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D007720:Knee Prosthesis; D008875:Middle Aged; D011475:Prosthesis Failure
D018712:Analgesics, Non-Narcotic; D004002:Clodronic Acid